Loading...
•
Jun 30, 2024
Gossamer Bio Q2 2024 Earnings Report
Announced financial results for the second quarter ended June 30, 2024 and provided a business update.
Key Takeaways
Gossamer Bio reported a net income of $49.2 million for the second quarter of 2024, with $354.5 million in cash, cash equivalents, and marketable securities as of June 30, 2024. Revenue from the sale of licenses was $88.8 million and revenue from contracts with collaborators was $7.1 million.
Cash, cash equivalents and marketable securities totaled $354.5 million as of June 30, 2024.
Revenue from the sale of licenses was $88.8 million, and revenue from contracts with collaborators was $7.1 million.
Research and Development expenses were $35.1 million.
Net income for the quarter was $49.2 million, or $0.22 basic net income per share.
Gossamer Bio
Gossamer Bio
Gossamer Bio Revenue by Segment
Revenue by Segment
Contracts with Collaborators Revenue
CapyFin.com Forward Guidance
The Company expects the combination of current cash, cash equivalents and marketable securities will be sufficient to fund its operating and capital expenditures into the first half of 2027.